NCT00910104View on ClinicalTrials.gov

Cholestasis Reversal: Efficacy of IV Fish Oil

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 23, 2019

Study Completion Date

January 23, 2019

Conditions
Parenteral Nutrition Associated Liver DiseaseShort Bowel SyndromeGastrointestinal Disease
Interventions
DRUG

Omegaven®

10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated

Trial Locations (1)

02115

Children's Hospital Boston, Boston

All Listed Sponsors
lead

Mark Puder

OTHER

NCT00910104 - Cholestasis Reversal: Efficacy of IV Fish Oil | Biotech Hunter | Biotech Hunter